… comorbidities, and evolving treatment options. Current epilepsy treatment emphasizes individualized, patient-centered … at the Cleveland Clinic Epilepsy Center, who addressed this … increase their likelihood of developing dementia. Emphasizing the importance …

… Food and Drug Administration (FDA) has approved an at- … -blind, randomized 20-week trial including 174 subjects.2 Patients … chronic insomnia, history of epilepsy or seizures, or neurological conditions … medication.2 It can be used as a standalone treatment …

… surgical evaluations, data show. “Epilepsy care generates an extraordinary amount … opportunities for advanced imaging, medication adjustments or surgical evaluation simply … /recruiting trials, guidelines Clinical Guidance, Healio CME, FDA news Healio…

… meaningful challenges for prognosis, treatment selection, and counseling, particularly … both clinical care and future trial design. During the meeting … counseling, therapeutic development, and multidisciplinary engagement across the epilepsy community. Click …

People taking some medications were much more likely to develop dementia, a … antimuscarinic drugs, anti-Parkinson drugs and epilepsy drugs. “The risks of this type of medication … antidepressants or alternative types of treatment for bladder conditions. These …

… of developing epilepsy; it only shows an association. “Additional randomized, controlled trials that … not respond to the current medications, so finding ways to reduce … people taking the GLP-1 drugs developed epilepsy, or 2.35%, compared to …

… years old, his epilepsy no longer responded to medications. He was having … -seizure medication will work. It was time to start exploring other treatment … information would be needed to develop a treatment plan. To get a …

… we had four main drugs for focal epilepsy. Now the number is … at injuries that occur and developing therapies to prevent seizures after … clinical trials and optimize treatment? We are limited by what the FDA will …

… molecule in development for the treatment of developmental and epileptic … Designation from the FDA for the treatment of SCN2A-DEE … across movement disorders and epilepsy, with four clinical- … uncertainties inherent in clinical trials; the expected timing of …

… data showing that individuals who develop epilepsy after midlife have substantially greater … lower disability, and rarely develop drug-resistant epilepsy (DRE) than those with … LOE is generally more treatment-responsive than epilepsy that begins earlier in …